MET amplification has been shown to be a mechanism of acquired resistance to combined BRAF and EGFR therapy in BRAF-V600E-mutant CRC and can respond to crizotinib.9 However, in this case, the patient was treated and responded to second-line chemotherapy FOLFIRI. The gene discussed is BRAF; the disease is colorectal carcinoma.